News | RIVM

From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26

From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.

Tailor-made information will help immigrants make decisions on taking part in screening programmes

Immigrants are relatively less likely to take part in preventive screening programmes, such as cancer screening. This is partly due to the language barrier and a lack of knowledge, according to a doctoral thesis by Nora Hamdiui.

Ten years of Tick Radar 80,000 tick bite reports; chances of being bitten highest in Drenthe

After recording 80,000 tick bites in 10 years via Tekenradar.nl, we now know that you are most likely to be bitten by a tick in Drenthe. Quickly removing the tick halves the chance of contracting Lyme disease.

Breast cancer screening resumes on Bonaire after COVID-19 hiatus

Women aged 50 to 75 years on Bonaire can participate in the breast cancer screening programme again as of Wednesday, May 26, 2021. This was temporarily halted in 2020 due to the COVID-19 pandemic.

Spread of tick-borne encephalitis virus in the Netherlands

Every year about 1.5 million ticks bite someone in the Netherlands, especially between March and October. Most people will not get sick of that.

Population screening programmes temporarily on hold

Due to the novel coronavirus (COVID-19) outbreak, the health care capacity in the Netherlands is expected to come under severe pressure in the coming period.

New test has no added value in Lyme disease of the central nervous system

Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.

Lyme disease costs EUR 20 million annually

The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.

Guus Velders in Nature's "Ten people that mattered this year"

Researcher Dr Guus Velders of RIVM has made the Nature top-10 list of 2016. This means that, according to Nature, he was one of the 10 most influential scientists in 2016.

RIVM research basis for historic climate agreement on HFCs

Scientific research by RIVM’s Guus Velders stood partly at the basis of the HFC global climate agreement.